骨质疏松症与脊柱骨折

骨折为骨质疏松最为严重的并发症，骨质疏松性脊柱骨折既是发生再骨折的高危因素，又是预测再次骨折发生的最重要指标。脊柱骨折作为再次骨折的高危因素，它反映了患者骨结构的退变和骨强度(BMD)的下降。预测再次骨折发生的危险性时，结合骨密度降低和有无脊柱骨折，将更有价值。通过X线片可以对脊柱骨折进行评估和分级，Genant半定量法对脊椎骨折进行评估，不需测量椎体高度，较为简便、实用。在药物疗效的评估上，只有将BMD和脊柱骨折结合起来，结果才更为客观、准确。既能增加骨密度又能减少脊椎骨折发生的药物是最为理想的药物。

Osteoporosis and vertebral fracture

Fracture is the most serious complication caused by osteopor osis. Vertebral fracture in osteoporosis is a strong risk factor for new fractur es as well as an important parameter in prognosticating new fractures. As a stro ng risk factor, vertebral fracture reflects the degeneration of the structure of bone and the reduction of bone mineral density (BMD). Therefore, it is more val uable in predicting the risk of refracture when the reduction of BMD and vertebr al fracture is reflected. It is more convenient and easier to evaluate vertebral fracture by radiographic grading and semiquantitative grading scheme without me asuring the vertebral height. To evaluate the drugs for osteoporosis objectively and accurately, their effects on both BMD and vertebral fracture should be take n into consideration. The ideal drug should be one that can increase BMD and red uce the risk of vertebral fracture.